Frankfurt - Delayed Quote EUR

Sangamo Therapeutics, Inc. (GBY.F)

1.1414

+0.0952

+(9.10%)

As of 9:06:32 AM GMT+1. Market Open.

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other small-cap stocks. Fifteen small-cap stocks—predominantly under the technology sector—are taking center stage this year, boasting triple- to quadruple-digit performance in their […]

Insider Monkey 23 days ago

SGMO
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Zacks 28 days ago

PFE

SGMO

NVS
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.

Barrons.com 29 days ago

PFE

SGMO
Top Midday Decliners

Sangamo Therapeutics (SGMO) shares plunged 55%, a day after the company said its partner, Pfizer (PF

PREMIUM
MT Newswires 30 days ago

SGMO

COCP
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner

PREMIUM
MT Newswires 30 days ago

PFE

SGMO
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

The Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was

PREMIUM
MT Newswires 30 days ago

PFE

SGMO

COMP
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future

GuruFocus.com 30 days ago

PFE

SGMO
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Investopedia 30 days ago

SGMO

PFE
SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following announcements that pharmaceutical giant Pfizer Inc. (NYSE:PFE) terminated their hemophilia A gene therapy co-development agreement. As of 8:53 am on Tuesday, shares of the company declined anew by 50.85 percent to $1.08 each. The previous day’s trading also […]

Insider Monkey 30 days ago

PFE

SGMO
Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) terminated its partnership with the company. The two were collaborating on a gene therapy program to co-develop a treatment for hemophilia A. Sangamo is exploring "all options" to continue the program. Morning Brief co-hosts Madison Mills and Seana Smith break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith

Yahoo Finance Video 30 days ago

SGMO

PFE
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE). Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options to advance the program, including seeking a potential new colla

Benzinga last month

PFE

SGMO
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Pharmaceutical Technology last month

PFE

SGMO
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket trading Tuesday.

Investing.com last month

PFE

SGMO
Trending tickers: Tesla, Bitcoin, Sangamo, Endeavour

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK last month

GBPEUR=X

GBP=X

EUR=X
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.

Zacks last month

PFE

SGMO
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT

Business Wire last month

SGMO
Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […]

Insider Monkey last month

SGMO
Astellas and Sangamo sign capsid deal for neurological diseases

Sangamo will obtain an upfront licence fee of $20m from Astellas.

Pharmaceutical Technology last month

ALPMY

SGMO
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Astellas a worldwide exclusive license

PR Newswire last month

SGMO

ALPMF

ALPMY
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

RICHMOND, Calif. & TOKYO, December 19, 2024--Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Business Wire last month

ALPMF

ALPMY

SGMO

Performance Overview

Return	GBY.F	S&P 500
YTD	-52.28%	+3.22%
1-Year	+208.24%	+23.80%
3-Year	-76.06%	+37.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sangamo Therapeutics, Inc. (GBY.F)

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership

Top Midday Decliners

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership

Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse

Sangamo stock plummets 50% after Pfizer ends gene therapy deal

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership

Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

Trending tickers: Tesla, Bitcoin, Sangamo, Endeavour

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?

Astellas and Sangamo sign capsid deal for neurological diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Performance Overview